The FDA reportedly assembled an advisory panel composed of individuals who sell peptides. That panel subsequently voted to greenlight a product. The outcome raises questions about the panel's composition and potential conflicts of interest.
The U.S. Food and Drug Administration reportedly stacked an advisory panel with individuals who sell peptides. This means the panel members were not independent experts but rather people whose business interests could be affected by the panel's decision. The agency's choice of panelists has drawn attention because of the apparent conflict of interest.
That same panel voted to greenlight a product. The exact nature of the product was not specified, but given the panel's composition of peptide sellers, the voted-on item likely pertains to a peptide-based treatment or diagnostic. The vote outcome was approval, meaning the panel recommended that the FDA allow the product to move forward.
The stacking of a regulatory panel with sellers of the very products under review raises concerns about objectivity. While FDA advisory panels typically include experts from various backgrounds, the inclusion of those with direct financial stakes in the outcome can undermine public trust. The decision to greenlight the product may be seen as predictable given the panel's makeup.
This episode highlights ongoing debates about conflicts of interest in regulatory processes. The FDA's reliance on outside experts is intended to provide scientific guidance, but when those experts have commercial ties, the integrity of the recommendation can be questioned. The vote to greenlight a product under these circumstances will likely fuel calls for stricter disclosure and recusal rules.
Related reading: FDA Advisory Panel Backs Peptide Compounding Despite Staff Objections, Bachem H1 2026 Slides Report 7% Sales Growth from Peptide Demand, FDA Panel Vote Could Expand Access to Popular Peptides for Millions, Precision Peptide Expands Nationwide Sales After FDA Panel Backs Six of Seven Peptides.